These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34468781)

  • 1. Eribulin improves tumor oxygenation demonstrated by
    Bo T; Yasui H; Shiga T; Shibata Y; Fujimoto M; Suzuki M; Higashikawa K; Miyamoto N; Inanami O; Kuge Y
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):821-833. PubMed ID: 34468781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel PET Probe "[
    Shimizu Y; Zhao S; Yasui H; Nishijima KI; Matsumoto H; Shiga T; Tamaki N; Ogawa M; Kuge Y
    Mol Imaging Biol; 2019 Feb; 21(1):122-129. PubMed ID: 29845425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of [
    Nakata N; Kiriu M; Okumura Y; Zhao S; Nishijima KI; Shiga T; Tamaki N; Kuge Y; Matsumoto H
    Nucl Med Biol; 2019 Mar; 70():39-45. PubMed ID: 30836255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of tumor hypoxia by eribulin demonstrated by
    Zhao S; Yu W; Ukon N; Tan C; Nishijima KI; Shimizu Y; Higashikawa K; Shiga T; Yamashita H; Tamaki N; Kuge Y
    EJNMMI Res; 2019 Jun; 9(1):51. PubMed ID: 31161539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution and radiation dosimetry of the novel hypoxia PET probe [
    Watanabe S; Shiga T; Hirata K; Magota K; Okamoto S; Toyonaga T; Higashikawa K; Yasui H; Kobayashi J; Nishijima KI; Iseki K; Matsumoto H; Kuge Y; Tamaki N
    EJNMMI Res; 2019 Jul; 9(1):60. PubMed ID: 31278504
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    De Bruycker S; Vangestel C; Van den Wyngaert T; Pauwels P; Wyffels L; Staelens S; Stroobants S
    J Nucl Med; 2019 Jan; 60(1):34-40. PubMed ID: 29980581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
    Funahashi Y; Okamoto K; Adachi Y; Semba T; Uesugi M; Ozawa Y; Tohyama O; Uehara T; Kimura T; Watanabe H; Asano M; Kawano S; Tizon X; McCracken PJ; Matsui J; Aoshima K; Nomoto K; Oda Y
    Cancer Sci; 2014 Oct; 105(10):1334-42. PubMed ID: 25060424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-time Tumor Oxygenation Changes After Single High-dose Radiation Therapy in Orthotopic and Subcutaneous Lung Cancer in Mice: Clinical Implication for Stereotactic Ablative Radiation Therapy Schedule Optimization.
    Song C; Hong BJ; Bok S; Lee CJ; Kim YE; Jeon SR; Wu HG; Lee YS; Cheon GJ; Paeng JC; Carlson DJ; Kim HJ; Ahn GO
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):1022-1031. PubMed ID: 27130790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
    Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Takahashi K; Fujita H; Shibutani M; Amano R; Takashima T; Tomita S; Hirakawa K; Ohira M
    BMC Cancer; 2020 Dec; 20(1):1215. PubMed ID: 33302911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
    Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
    Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eribulin induces tumor vascular remodeling through intussusceptive angiogenesis in a sarcoma xenograft model.
    Taguchi E; Horiuchi K; Senoo A; Susa M; Inoue M; Ishizaka T; Rikitake H; Matsuhashi Y; Chiba K
    Biochem Biophys Res Commun; 2021 Sep; 570():89-95. PubMed ID: 34274851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models.
    Ito K; Hamamichi S; Abe T; Akagi T; Shirota H; Kawano S; Asano M; Asano O; Yokoi A; Matsui J; Umeda IO; Fujii H
    Cancer Sci; 2017 Nov; 108(11):2273-2280. PubMed ID: 28869796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma.
    Miki S; Imamichi S; Fujimori H; Tomiyama A; Fujimoto K; Satomi K; Matsushita Y; Matsuzaki S; Takahashi M; Ishikawa E; Yamamoto T; Matsumura A; Mukasa A; Nishikawa R; Masutomi K; Narita Y; Masutani M; Ichimura K
    Cancer Sci; 2018 Jul; 109(7):2275-2285. PubMed ID: 29758120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms.
    Asano M; Matsui J; Towle MJ; Wu J; McGonigle S; DE Boisferon MH; Uenaka T; Nomoto K; Littlefield BA
    Anticancer Res; 2018 Jun; 38(6):3375-3385. PubMed ID: 29848686
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Yu W; Qiao F; Su X; Zhang D; Wang H; Jiang J; Xu H
    Biomed Pharmacother; 2019 Nov; 119():109454. PubMed ID: 31526971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
    Chitneni SK; Bida GT; Yuan H; Palmer GM; Hay MP; Melcher T; Wilson WR; Zalutsky MR; Dewhirst MW
    J Nucl Med; 2013 Aug; 54(8):1339-46. PubMed ID: 23740105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effects of Pulsed Radiation Therapy on Tumor Oxygenation in 2 Murine Models of Head and Neck Squamous Cell Carcinoma.
    Wobb J; Krueger SA; Kane JL; Galoforo S; Grills IS; Wilson GD; Marples B
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):820-8. PubMed ID: 26104936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
    Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
    Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
    Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia imaging with
    Melsens E; De Vlieghere E; Descamps B; Vanhove C; Kersemans K; De Vos F; Goethals I; Brans B; De Wever O; Ceelen W; Pattyn P
    Radiat Oncol; 2018 Mar; 13(1):39. PubMed ID: 29514673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.